Which has preferable earnings and valuation, ALKS or MEDP?

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 5.43 $241.66M $0.90 53.46 Medpace $2.53B 5.34 $451.12M $15.91 29.76

Is ALKS or MEDP more profitable?

Medpace has a net margin of 17.19% compared to Alkermes' net margin of 9.78%. Medpace's return on equity of 120.89% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 9.78% 9.26% 5.66% Medpace 17.19% 120.89% 24.79%

Does the media refer more to ALKS or MEDP?

In the previous week, Alkermes had 5 more articles in the media than Medpace. MarketBeat recorded 9 mentions for Alkermes and 4 mentions for Medpace. Alkermes' average media sentiment score of 1.11 beat Medpace's score of 0.96 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, OMCL or ALKS?

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.47 $2.05M $0.44 87.30 Alkermes $1.48B 5.43 $241.66M $0.90 53.46

Is OMCL or ALKS more profitable?

Alkermes has a net margin of 9.78% compared to Omnicell's net margin of 1.67%. Alkermes' return on equity of 9.26% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Alkermes 9.78% 9.26% 5.66%

Does the media favor AMN or ALKS?

In the previous week, AMN Healthcare Services had 5 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for AMN Healthcare Services and 9 mentions for Alkermes. Alkermes' average media sentiment score of 1.11 beat AMN Healthcare Services' score of 0.31 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Alkermes 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or ALKS?

In the previous week, United Therapeutics had 10 more articles in the media than Alkermes. MarketBeat recorded 19 mentions for United Therapeutics and 9 mentions for Alkermes. Alkermes' average media sentiment score of 1.11 beat United Therapeutics' score of 0.70 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alkermes (ALKS) Competitors

$48.11 +2.09 (+4.54%)

Closing price 03:58 PM Eastern

Extended Trading

$48.36 +0.25 (+0.52%)

As of 07:44 PM Eastern

Compare

ALKS vs. ABEO, MEDP, OMCL, AMN, and UTHR

Should you buy Alkermes stock or one of its competitors? MarketBeat compares Alkermes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.

How does Alkermes compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	56.01	$71.18M	$0.97	5.90
Alkermes	$1.48B	5.43	$241.66M	$0.90	53.46

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abeona Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

In the previous week, Alkermes had 9 more articles in the media than Abeona Therapeutics. MarketBeat recorded 9 mentions for Alkermes and 0 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 1.11 beat Abeona Therapeutics' score of -0.05 indicating that Alkermes is being referred to more favorably in the news media.

Company	Overall Sentiment
Abeona Therapeutics	Neutral
Alkermes	Positive

Alkermes has a net margin of 9.78% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Alkermes	9.78%	9.26%	5.66%

Abeona Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 232.17%. Alkermes has a consensus price target of $46.63, suggesting a potential downside of 3.09%. Given Abeona Therapeutics' higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alkermes	0 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Alkermes beats Abeona Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Alkermes compare to Medpace?

Alkermes (NASDAQ:ALKS) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.43	$241.66M	$0.90	53.46
Medpace	$2.53B	5.34	$451.12M	$15.91	29.76

Alkermes presently has a consensus target price of $46.63, suggesting a potential downside of 3.09%. Medpace has a consensus target price of $467.08, suggesting a potential downside of 1.35%. Given Medpace's higher probable upside, analysts clearly believe Medpace is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.78
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Alkermes has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

In the previous week, Alkermes had 5 more articles in the media than Medpace. MarketBeat recorded 9 mentions for Alkermes and 4 mentions for Medpace. Alkermes' average media sentiment score of 1.11 beat Medpace's score of 0.96 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.19% compared to Alkermes' net margin of 9.78%. Medpace's return on equity of 120.89% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Medpace	17.19%	120.89%	24.79%

Summary

Medpace beats Alkermes on 9 of the 17 factors compared between the two stocks.

How does Alkermes compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Alkermes had 9 more articles in the media than Omnicell. MarketBeat recorded 9 mentions for Alkermes and 0 mentions for Omnicell. Alkermes' average media sentiment score of 1.11 beat Omnicell's score of 0.00 indicating that Alkermes is being referred to more favorably in the news media.

Company	Overall Sentiment
Omnicell	Neutral
Alkermes	Positive

Alkermes has a net margin of 9.78% compared to Omnicell's net margin of 1.67%. Alkermes' return on equity of 9.26% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Alkermes	9.78%	9.26%	5.66%

Omnicell has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Omnicell presently has a consensus price target of $59.86, indicating a potential upside of 55.84%. Alkermes has a consensus price target of $46.63, indicating a potential downside of 3.09%. Given Omnicell's stronger consensus rating and higher possible upside, equities analysts clearly believe Omnicell is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Alkermes	0 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.78

97.7% of Omnicell shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.9% of Omnicell shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.47	$2.05M	$0.44	87.30
Alkermes	$1.48B	5.43	$241.66M	$0.90	53.46

Summary

Alkermes beats Omnicell on 11 of the 16 factors compared between the two stocks.

How does Alkermes compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Alkermes has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.44	-$95.70M	-$0.87	N/A
Alkermes	$1.48B	5.43	$241.66M	$0.90	53.46

AMN Healthcare Services currently has a consensus target price of $27.00, indicating a potential downside of 13.16%. Alkermes has a consensus target price of $46.63, indicating a potential downside of 3.09%. Given Alkermes' stronger consensus rating and higher possible upside, analysts clearly believe Alkermes is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Alkermes	0 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, AMN Healthcare Services had 5 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for AMN Healthcare Services and 9 mentions for Alkermes. Alkermes' average media sentiment score of 1.11 beat AMN Healthcare Services' score of 0.31 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alkermes	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Alkermes has a net margin of 9.78% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Alkermes	9.78%	9.26%	5.66%

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alkermes beats AMN Healthcare Services on 12 of the 17 factors compared between the two stocks.

How does Alkermes compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

United Therapeutics presently has a consensus target price of $619.42, indicating a potential upside of 13.79%. Alkermes has a consensus target price of $46.63, indicating a potential downside of 3.09%. Given United Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe United Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Alkermes	0 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.78

United Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

In the previous week, United Therapeutics had 10 more articles in the media than Alkermes. MarketBeat recorded 19 mentions for United Therapeutics and 9 mentions for Alkermes. Alkermes' average media sentiment score of 1.11 beat United Therapeutics' score of 0.70 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher revenue and earnings than Alkermes. United Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.26	$1.33B	$27.09	20.09
Alkermes	$1.48B	5.43	$241.66M	$0.90	53.46

United Therapeutics has a net margin of 40.62% compared to Alkermes' net margin of 9.78%. United Therapeutics' return on equity of 19.24% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Alkermes	9.78%	9.26%	5.66%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 4.6% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

United Therapeutics beats Alkermes on 12 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALKS vs. The Competition

Export

Metric	Alkermes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.67B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	53.46	19.75	24.92	23.97
Price / Sales	5.43	329.42	528.81	109.59
Price / Cash	27.49	128.56	44.82	54.51
Price / Book	4.37	8.29	10.79	6.50
Net Income	$241.66M	$23.85M	$3.56B	$336.88M
7 Day Performance	9.12%	5.21%	1.67%	-0.22%
1 Month Performance	30.73%	2.19%	0.43%	0.77%
1 Year Performance	64.42%	60.99%	32.84%	31.57%

Alkermes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALKS Alkermes	2.3922 of 5 stars	$48.11 +4.5%	$46.63 -3.1%	+58.2%	$7.67B	$1.48B	53.46	2,050	Positive News Analyst Forecast
ABEO Abeona Therapeutics	2.8479 of 5 stars	$5.67 +2.5%	$19.00 +235.1%	-2.4%	$315.18M	$5.82M	5.85	90
MEDP Medpace	2.2245 of 5 stars	$467.50 +0.0%	$467.08 -0.1%	+47.3%	$13.35B	$2.53B	29.38	6,200
OMCL Omnicell	3.1081 of 5 stars	$39.99 +5.7%	$59.86 +49.7%	+38.0%	$1.72B	$1.18B	90.89	3,580
AMN AMN Healthcare Services	1.7005 of 5 stars	$30.88 +0.2%	$25.29 -18.1%	+38.6%	$1.19B	$2.73B	N/A	2,664	News Coverage Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALKS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and UTHR

How does Alkermes compare to Abeona Therapeutics?

Summary

How does Alkermes compare to Medpace?

Summary

How does Alkermes compare to Omnicell?

Summary

How does Alkermes compare to AMN Healthcare Services?

Summary

How does Alkermes compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and UTHR

How does Alkermes compare to Abeona Therapeutics?

Which has preferable valuation and earnings, ABEO or ALKS?

Do insiders & institutionals believe in ABEO or ALKS?

Which has more risk & volatility, ABEO or ALKS?

Does the media favor ABEO or ALKS?

Is ABEO or ALKS more profitable?

Do analysts prefer ABEO or ALKS?

Summary

How does Alkermes compare to Medpace?

Do insiders & institutionals hold more shares of ALKS or MEDP?

Which has preferable earnings and valuation, ALKS or MEDP?

Do analysts recommend ALKS or MEDP?

Which has more volatility & risk, ALKS or MEDP?

Does the media refer more to ALKS or MEDP?

Is ALKS or MEDP more profitable?

Summary

How does Alkermes compare to Omnicell?

Does the media favor OMCL or ALKS?

Is OMCL or ALKS more profitable?

Which has more volatility and risk, OMCL or ALKS?

Do analysts recommend OMCL or ALKS?

Do insiders and institutionals have more ownership in OMCL or ALKS?

Which has higher earnings and valuation, OMCL or ALKS?

Summary

How does Alkermes compare to AMN Healthcare Services?

Which has preferable valuation and earnings, AMN or ALKS?

Do analysts prefer AMN or ALKS?

Does the media favor AMN or ALKS?

Which has more volatility & risk, AMN or ALKS?

Is AMN or ALKS more profitable?

Do institutionals & insiders have more ownership in AMN or ALKS?

Summary

How does Alkermes compare to United Therapeutics?

Do analysts rate UTHR or ALKS?

Which has more risk & volatility, UTHR or ALKS?

Does the media favor UTHR or ALKS?

Which has stronger earnings and valuation, UTHR or ALKS?

Is UTHR or ALKS more profitable?

Do institutionals and insiders have more ownership in UTHR or ALKS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools